Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemia

Abstract excerpt

Ibrutinib is highly active in Waldenström macroglobulinaemia (WM) patients, but disease progression can occur due to acquired mutations in BTK, the target of ibrutinib, or PLCG2, the protein downstream of BTK. However, not all resistant patients harbour these alterations. We have performed a whole-exome sequencing study to identify alternative molecular mechanisms that can drive ibrutinib resistance. Our findings...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to Immunodeficiency and Autoimmune Disorders
• Share to Lymphoma Diagnosis and Treatment